Basic Information
LONSURF FILM-COATED TABLET 20MG/8.19MG
TABLET, FILM COATED
Regulatory Information
SIN15494P
May 24, 2018
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XL01BC59
Company Information
TAIHO PHARMA ASIA PACIFIC PTE. LTD.
TAIHO PHARMA ASIA PACIFIC PTE. LTD.
Active Ingredients
Strength: 20mg
Strength: 8.19mg
Detailed Information
Contraindications
**4 CONTRAINDICATIONS** None.
Indication Information
**1 INDICATIONS AND USAGE** **1.1 Metastatic Colorectal Cancer** Lonsurf® is indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. **1.2 Metastatic Gastric Cancer** Lonsurf® is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma who have been previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neutargeted therapy.